Highlights

  • OncoSil Medical (ASX:OSL) closed at AUD 1.21 on 10 August 2026, down 2.81% or AUD 0.035 during the session.
  • The company has progressed its US Humanitarian Device Exemption application for treatment of distal cholangiocarcinoma.
  • OncoSil received Australian Therapeutic Goods Administration approval for locally advanced pancreatic cancer in May 2026.
  • Commercial activity has continued across Europe, alongside clinical development and expansion of active implanting centres.

OncoSil Medical (ASX:OSL) is developing a targeted internal radiation treatment designed for difficult-to-treat cancers, with current activities spanning regulatory approvals, clinical development and commercial expansion.

Its OncoSil device uses phosphorus-32 microparticles implanted directly into a tumour under endoscopic ultrasound guidance, generally alongside chemotherapy.

The company already has regulatory clearance in selected markets and is seeking to expand its commercial footprint further.

OncoSil Medical closed at AUD 1.21 on 10 August 2026, down 2.81% or AUD 0.035 during the session.

US Regulatory Pathway Remains in Focus

A key development for OncoSil is its Humanitarian Device Exemption application with the US Food and Drug Administration for use in distal cholangiocarcinoma.

The final submission was lodged on 2 July 2026 following progression through the regulatory review process.

The Humanitarian Device Exemption pathway applies to medical devices intended to treat conditions affecting relatively small patient populations.

The company has indicated that substantive questions raised during the review had been addressed, with the regulatory process moving into its final stages.

For OncoSil Medical (ASX:OSL), successful progression through the US regulatory pathway would provide a foundation for future commercialisation activities in the market.

Australian Approval Adds Another Commercial Market

OncoSil secured Australian Therapeutic Goods Administration approval on 20 May 2026 for the treatment of locally advanced pancreatic cancer.

The approval expanded the company's regulatory footprint alongside its existing CE Mark in Europe.

OncoSil's technology is designed to deliver targeted internal radiation directly into tumour tissue, with the aim of concentrating treatment around the cancer while limiting exposure to surrounding areas.

The company continues working on commercial adoption across markets where regulatory approvals are already in place.

European Commercial Activity Progresses

OncoSil has also reported increased commercial activity across its European operations.

Dose sales increased approximately 60% year-on-year during Q3 FY2026, while the number of commercially active treating centres increased 56% to 28.

A July 2026 investor presentation subsequently reported 31 active implanting centres across Germany, Spain, Italy and Turkey during H1 CY2026.

The expansion of implanting centres is an important part of the company's commercial strategy as it seeks to increase adoption among specialist treatment providers.

Clinical Program Supports Broader Evidence Base

OncoSil Medical (ASX:OSL) continues to develop clinical evidence supporting its technology.

The TRIPP-FFX study enrolled 88 patients and met both co-primary endpoints relating to safety and 16-week local disease control.

The study was non-comparative and was not designed to establish head-to-head efficacy against other treatments.

The company has also been selected for participation in the EU-funded PALACROS consortium, supporting the PULSE Phase II clinical trial.

OncoSil estimated that participation in the consortium could represent approximately AUD 9 million in trial-related cost savings.

Financial Position Reflects Commercialisation Stage

OncoSil remains a pre-profit medical technology company investing in regulatory approvals, clinical development and commercial expansion.

FY2025 Revenue increased approximately 127% year-on-year to around AUD 1.2 million.

However, the company reported a net loss of approximately AUD 15.1 million for the period, increasing approximately 27%.

Net tangible assets per security declined from AUD 0.5732 to AUD 0.2186.

The company's July 2026 presentation reported cash of AUD 9.3 million as at 31 March 2026.

The financial position highlights the importance of increasing commercial revenue while managing ongoing clinical, regulatory and operating expenditure.

Commercial Scale Remains the Longer-Term Test

OncoSil has outlined a broader commercial opportunity for its technology across pancreatic and bile-duct cancer treatment.

Management has referred to a potential AUD 98 million revenue opportunity at approximately 70% gross Margin once its proposed Sydney Manufacturing Facility reaches scale.

The company has also referenced a global addressable market of approximately US$4.2 billion.

These figures represent management estimates of potential future opportunity rather than contracted or recognised revenue.

For OncoSil, the longer-term Investment case will depend on regulatory approvals translating into physician adoption, reimbursement coverage, treatment volumes and recurring commercial revenue.

Outlook

OncoSil Medical's near-term focus remains on progressing its US regulatory pathway, expanding commercial adoption across approved markets and building the clinical evidence supporting its technology. Key areas to monitor include the outcome of the FDA Humanitarian Device Exemption process, growth in active treatment centres, dose sales, reimbursement progress and Cash Management . Beyond regulatory milestones, the company's ability to convert approvals into sustainable commercial revenue will be central to determining the next phase of its development.